MILAN — Pediatric patients experienced improved psoriasis symptoms and quality of life with ixekizumab treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.
“About 1% of children and adolescents worldwide are affected by plaque psoriasis (PsO),” Andreas Pinter, MD, medical director of clinical research and senior physician in